Biogen By Buying Nightstar Targets Ophthalmology As Emerging Growth Area
Biogen is paying around $800m cash to buy UK-based Nightstar Therapeutics, which focuses on gene therapy for retinal diseases.
You may also be interested in...
Biogen will pay Denali $560m up front plus a $465m equity investment in exchange for co-development and co-commercialization rights to clinical-stage LRRK2 inhibitors for Parkinson's disease.
Japanese company joins the ranks of big pharma buying up gene therapy pioneers
As once-star investment funds fail, another major investor argues this is opportunity for UK biotech to demonstrate staying power.